Regulatory effects of Lactobacillus plantarum HY7714 on skin health by improving intestinal condition

Bora Nam, Soo A Kim, Soo Dong Park, Hyeon Ji Kim, Ji Soo Kim, Chu Hyun Bae, Joo Yun Kim, Woo Nam, Jung Lyoul Lee, Jae Hun Sim, Bora Nam, Soo A Kim, Soo Dong Park, Hyeon Ji Kim, Ji Soo Kim, Chu Hyun Bae, Joo Yun Kim, Woo Nam, Jung Lyoul Lee, Jae Hun Sim

Abstract

Despite increasing research on the gut-skin axis, there is a lack of comprehensive studies on the improvement of skin health through the regulation of the intestinal condition in humans. In this study, we investigated the benefits of Lactobacillus plantarum HY7714 (HY7714) consumption on skin health through its modulatory effects on the intestine and ensuing immune responses. HY7714 consumption led to differences in bacterial abundances from phylum to genus level, including increases in Actinobacteria followed by Bifidobacterium and a decrease in Proteobacteria. Additionally, HY7714 significantly ameliorated inflammation by reducing matrix metallopeptidases (MMP-2 and MMP-9), zonulin, and calprotectin in plasma, all of which are related to skin and intestinal permeability. Furthermore, RNA-seq analysis revealed its efficacy at restoring the integrity of the gut barrier by regulating gene expression associated with the extracellular matrix and immunity. This was evident by the upregulation of IGFBP5, SERPINE1, EFEMP1, COL6A3, and SEMA3B and downregulation of MT2A, MT1E, MT1X, MT1G, and MT1F between TNF- α and TNF- α plus HY7714 treated Caco-2 cells. These results propose the potential mechanistic role of HY7714 on skin health by the regulation of the gut condition.

Conflict of interest statement

The author have read the journal's policy and the authors of this manuscript have the following competing interests: Authors [BN, SAK, SDP, HJK, JSK, CHB, JYK, WN, JLL and JHS] are paid employees of Korea Yakult Co. Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.

Figures

Fig 1. Flow chart of the study.
Fig 1. Flow chart of the study.
Fig 2. RNA-seq data and gene ontology…
Fig 2. RNA-seq data and gene ontology analysis of TNF-α and TNF-α plus HY7714 treated Caco-2 cell.
(A) Volcano plot between TNF-α and TNF-α plus HY7714 treatment. FC (fold change) > 2 was accepted as differentially expressed; red: up-regulated and blue: down-regulated. DEGs are analyzed by GO terms. The number of categories in each GO (B), and the top 20 GO terms up regulated (C) and down regulated (D). Yellow, green, and black indicate genes that belongs to the molecular function, biological process, and cellular component categories. Terms were considered significant at p

Fig 3. Gut microbial composition in PPS…

Fig 3. Gut microbial composition in PPS groups before and after HY7714 consumption at 4…

Fig 3. Gut microbial composition in PPS groups before and after HY7714 consumption at 4 and 8 wk.
Sequence summary in fecal samples; the number of reads, operational taxonomic units (OTUs), and Shannon index of alpha diversity (A). Relative abundances of gut microbial composition at the phylum (B), family (C) and genus levels (D). Data are analyzed using the Wilcoxon signed-rank test. Results are expressed as the Mean ± SEM. Asterisks (* and **) indicate a significant difference (p

Fig 4. Comparison of biomarker concentrations in…

Fig 4. Comparison of biomarker concentrations in plasma.

Changes in Zonulin(A), Calprotectin(B), MMP-2(C) and MMP-9(D)…

Fig 4. Comparison of biomarker concentrations in plasma.
Changes in Zonulin(A), Calprotectin(B), MMP-2(C) and MMP-9(D) levels in plasma before and after HY7714 consumption over 8 wk. Data are analyzed using the Wilcoxon signed-rank test. Results are expressed as Mean ± SEM. Asterisks (* and **) indicate a significant difference (p
Similar articles
Cited by
References
    1. O'Neill CA, Monteleone G, McLaughlin JT, Paus R (2016) The gut-skin axis in health and disease: A paradigm with therapeutic implications. Bioessays 38: 1167–1176. 10.1002/bies.201600008 - DOI - PubMed
    1. Saarialho-Kere U (2004) The gut-skin axis. J Pediatr Gastroenterol Nutr 39 Suppl 3: S734–735. 10.1097/00005176-200406003-00009 - DOI - PubMed
    1. Bowe WP, Logan AC (2011) Acne vulgaris, probiotics and the gut-brain-skin axis—back to the future? Gut Pathog 3: 1 10.1186/1757-4749-3-1 - DOI - PMC - PubMed
    1. Levkovich T, Poutahidis T, Smillie C, Varian BJ, Ibrahim YM, et al. (2013) Probiotic bacteria induce a 'glow of health'. PLoS One 8: e53867 10.1371/journal.pone.0053867 - DOI - PMC - PubMed
    1. Han Y, Kim B, Ban J, Lee J, Kim BJ, et al. (2012) A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol 23: 667–673. 10.1111/pai.12010 - DOI - PubMed
Show all 50 references
Publication types
MeSH terms
Grant support
Korea Yakult Co. Ltd. provided support for this study in the form salaries for authors [BN, SAK, SDP, HJK, JSK, CHB, JYK, WN, JLL and JHS]. The specific roles of these authors are articulated in the 'author contributions' section. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Fig 3. Gut microbial composition in PPS…
Fig 3. Gut microbial composition in PPS groups before and after HY7714 consumption at 4 and 8 wk.
Sequence summary in fecal samples; the number of reads, operational taxonomic units (OTUs), and Shannon index of alpha diversity (A). Relative abundances of gut microbial composition at the phylum (B), family (C) and genus levels (D). Data are analyzed using the Wilcoxon signed-rank test. Results are expressed as the Mean ± SEM. Asterisks (* and **) indicate a significant difference (p

Fig 4. Comparison of biomarker concentrations in…

Fig 4. Comparison of biomarker concentrations in plasma.

Changes in Zonulin(A), Calprotectin(B), MMP-2(C) and MMP-9(D)…

Fig 4. Comparison of biomarker concentrations in plasma.
Changes in Zonulin(A), Calprotectin(B), MMP-2(C) and MMP-9(D) levels in plasma before and after HY7714 consumption over 8 wk. Data are analyzed using the Wilcoxon signed-rank test. Results are expressed as Mean ± SEM. Asterisks (* and **) indicate a significant difference (p
Similar articles
Cited by
References
    1. O'Neill CA, Monteleone G, McLaughlin JT, Paus R (2016) The gut-skin axis in health and disease: A paradigm with therapeutic implications. Bioessays 38: 1167–1176. 10.1002/bies.201600008 - DOI - PubMed
    1. Saarialho-Kere U (2004) The gut-skin axis. J Pediatr Gastroenterol Nutr 39 Suppl 3: S734–735. 10.1097/00005176-200406003-00009 - DOI - PubMed
    1. Bowe WP, Logan AC (2011) Acne vulgaris, probiotics and the gut-brain-skin axis—back to the future? Gut Pathog 3: 1 10.1186/1757-4749-3-1 - DOI - PMC - PubMed
    1. Levkovich T, Poutahidis T, Smillie C, Varian BJ, Ibrahim YM, et al. (2013) Probiotic bacteria induce a 'glow of health'. PLoS One 8: e53867 10.1371/journal.pone.0053867 - DOI - PMC - PubMed
    1. Han Y, Kim B, Ban J, Lee J, Kim BJ, et al. (2012) A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol 23: 667–673. 10.1111/pai.12010 - DOI - PubMed
Show all 50 references
Publication types
MeSH terms
Grant support
Korea Yakult Co. Ltd. provided support for this study in the form salaries for authors [BN, SAK, SDP, HJK, JSK, CHB, JYK, WN, JLL and JHS]. The specific roles of these authors are articulated in the 'author contributions' section. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Fig 4. Comparison of biomarker concentrations in…
Fig 4. Comparison of biomarker concentrations in plasma.
Changes in Zonulin(A), Calprotectin(B), MMP-2(C) and MMP-9(D) levels in plasma before and after HY7714 consumption over 8 wk. Data are analyzed using the Wilcoxon signed-rank test. Results are expressed as Mean ± SEM. Asterisks (* and **) indicate a significant difference (p

References

    1. O'Neill CA, Monteleone G, McLaughlin JT, Paus R (2016) The gut-skin axis in health and disease: A paradigm with therapeutic implications. Bioessays 38: 1167–1176. 10.1002/bies.201600008
    1. Saarialho-Kere U (2004) The gut-skin axis. J Pediatr Gastroenterol Nutr 39 Suppl 3: S734–735. 10.1097/00005176-200406003-00009
    1. Bowe WP, Logan AC (2011) Acne vulgaris, probiotics and the gut-brain-skin axis—back to the future? Gut Pathog 3: 1 10.1186/1757-4749-3-1
    1. Levkovich T, Poutahidis T, Smillie C, Varian BJ, Ibrahim YM, et al. (2013) Probiotic bacteria induce a 'glow of health'. PLoS One 8: e53867 10.1371/journal.pone.0053867
    1. Han Y, Kim B, Ban J, Lee J, Kim BJ, et al. (2012) A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol 23: 667–673. 10.1111/pai.12010
    1. Gueniche A, Philippe D, Bastien P, Reuteler G, Blum S, et al. (2014) Randomised double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity. Benef Microbes 5: 137–145. 10.3920/BM2013.0001
    1. Ra J, Lee DE, Kim SH, Jeong JW, Ku HK, et al. (2014) Effect of oral administration of Lactobacillus plantarum HY7714 on epidermal hydration in ultraviolet B-irradiated hairless mice. J Microbiol Biotechnol 24: 1736–1743. 10.4014/jmb.1408.08023
    1. Kim HM, Lee DE, Park SD, Kim YT, Kim YJ, et al. (2014) Oral administration of Lactobacillus plantarum HY7714 protects hairless mouse against ultraviolet B-induced photoaging. J Microbiol Biotechnol 24: 1583–1591. 10.4014/jmb.1406.06038
    1. Lee DE, Huh CS, Ra J, Choi ID, Jeong JW, et al. (2015) Clinical Evidence of Effects of Lactobacillus plantarum HY7714 on Skin Aging: A Randomized, Double Blind, Placebo-Controlled Study. J Microbiol Biotechnol 25: 2160–2168. 10.4014/jmb.1509.09021
    1. Kumar Bajaj B, Claes IJ, Lebeer S (2015) Functional mechanisms of probiotics. Journal of microbiology, biotechnology and food sciences—4: 321–327.
    1. Brown M (2011) Modes of action of probiotics: recent developments. Journal of animal and veterinary advances 10: 1895–1900.
    1. Nam B, Kim SA, Nam W, Jeung WH, Park SD, et al. (2019) Lactobacillus plantarum HY7714 Restores TNF-alpha Induced Defects on Tight Junctions. Prev Nutr Food Sci 24: 64–69. 10.3746/pnf.2019.24.1.64
    1. Chapat L, Chemin K, Dubois B, Bourdet-Sicard R, Kaiserlian D (2004) Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation. Eur J Immunol 34: 2520–2528. 10.1002/eji.200425139
    1. Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, et al. (2011) Recommendations for probiotic use-2011 update. J Clin Gastroenterol 45 Suppl: S168–171.
    1. Gueniche A, Benyacoub J, Buetler TM, Smola H, Blum S (2006) Supplementation with oral probiotic bacteria maintains cutaneous immune homeostasis after UV exposure. Eur J Dermatol 16: 511–517.
    1. Gueniche A, Bastien P, Ovigne JM, Kermici M, Courchay G, et al. (2010) Bifidobacterium longum lysate, a new ingredient for reactive skin. Exp Dermatol 19: e1–8. 10.1111/j.1600-0625.2009.00932.x
    1. Pinto M (1983) Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol cell 47: 323–330.
    1. Shannon CE (1948) A mathematical theory of communication. Bell system technical journal 27: 379–423.
    1. Huang LS, Kong C, Gao RY, Yan X, Yu HJ, et al. (2018) Analysis of fecal microbiota in patients with functional constipation undergoing treatment with synbiotics. Eur J Clin Microbiol Infect Dis 37: 555–563. 10.1007/s10096-017-3149-7
    1. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, et al. (1995) IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 5: 1–17.
    1. Nguyen XX, Muhammad L, Nietert PJ, Feghali-Bostwick C (2018) IGFBP-5 Promotes Fibrosis via Increasing Its Own Expression and That of Other Pro-fibrotic Mediators. Front Endocrinol (Lausanne) 9: 601.
    1. Wang J, Ding N, Li Y, Cheng H, Wang D, et al. (2015) Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncotarget 6: 20636–20649. 10.18632/oncotarget.4114
    1. Januchowski R, Zawierucha P, Rucinski M, Nowicki M, Zabel M (2014) Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int 2014: 365867 10.1155/2014/365867
    1. Hu J, Duan B, Jiang W, Fu S, Gao H, et al. (2019) Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B). Cancer Med 8: 3152–3166. 10.1002/cam4.2144
    1. Pang CH, Du W, Long J, Song LJ (2016) Mechanism of SEMA3B gene silencing and clinical significance in glioma. Genet Mol Res 15.
    1. Minna J, Tomizawa Y, Sekido Y, Lerman M (2010) SEMA3B inhibits tumor growth and induces apoptosis in cancer cells. Google Patents.
    1. Marakhonov AV, Tabakov VY, Zernov NV, Dadali EL, Sharkova IV, et al. (2018) Two novel COL6A3 mutations disrupt extracellular matrix formation and lead to myopathy from Ullrich congenital muscular dystrophy and Bethlem myopathy spectrum. Gene 672: 165–171. 10.1016/j.gene.2018.06.026
    1. Qi L, Higgins SP, Lu Q, Samarakoon R, Wilkins-Port CE, et al. (2008) SERPINE1 (PAI-1) is a prominent member of the early G0 —> G1 transition "wound repair" transcriptome in p53 mutant human keratinocytes. J Invest Dermatol 128: 749–753. 10.1038/sj.jid.5701068
    1. Mazzoccoli G, Pazienza V, Panza A, Valvano MR, Benegiamo G, et al. (2012) ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol 138: 501–511. 10.1007/s00432-011-1126-6
    1. Coyle P, Philcox JC, Carey LC, Rofe AM (2002) Metallothionein: the multipurpose protein. Cell Mol Life Sci 59: 627–647. 10.1007/s00018-002-8454-2
    1. Krizkova S, Ryvolova M, Hrabeta J, Adam V, Stiborova M, et al. (2012) Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metab Rev 44: 287–301. 10.3109/03602532.2012.725414
    1. Cummings JE, Kovacic JP (2009) The ubiquitous role of zinc in health and disease. J Vet Emerg Crit Care (San Antonio) 19: 215–240.
    1. Chen Q, Chen O, Martins IM, Hou H, Zhao X, et al. (2017) Collagen peptides ameliorate intestinal epithelial barrier dysfunction in immunostimulatory Caco-2 cell monolayers via enhancing tight junctions. Food Funct 8: 1144–1151. 10.1039/c6fo01347c
    1. Fasano A (2012) Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol 10: 1096–1100. 10.1016/j.cgh.2012.08.012
    1. Pool-Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, et al. (1996) Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer 26: 365–380. 10.1080/01635589609514492
    1. Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, et al. (2013) Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol 182: 1595–1606. 10.1016/j.ajpath.2013.01.013
    1. Chichlowski M, De Lartigue G, German JB, Raybould HE, Mills DA (2012) Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function. J Pediatr Gastroenterol Nutr 55: 321–327. 10.1097/MPG.0b013e31824fb899
    1. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, et al. (2014) Intestinal permeability—a new target for disease prevention and therapy. BMC Gastroenterol 14: 189 10.1186/s12876-014-0189-7
    1. Azad MAK, Sarker M, Li T, Yin J (2018) Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int 2018: 9478630 10.1155/2018/9478630
    1. Shin NR, Whon TW, Bae JW (2015) Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 33: 496–503. 10.1016/j.tibtech.2015.06.011
    1. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, et al. (2016) Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep 6: 28484 10.1038/srep28484
    1. Lun H, Yang W, Zhao S, Jiang M, Xu M, et al. (2019) Altered gut microbiota and microbial biomarkers associated with chronic kidney disease. Microbiologyopen 8: e00678 10.1002/mbo3.678
    1. Brahe LK, Le Chatelier E, Prifti E, Pons N, Kennedy S, et al. (2015) Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr Diabetes 5: e159 10.1038/nutd.2015.9
    1. Vaarala O, Atkinson MA, Neu J (2008) The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57: 2555–2562. 10.2337/db08-0331
    1. Mizuno K, Adachi E, Imamura Y, Katsumata O, Hayashi T (2001) The fibril structure of type V collagen triple-helical domain. Micron 32: 317–323. 10.1016/s0968-4328(00)00036-6
    1. Wei Z, Cao S, Liu S, Yao Z, Sun T, et al. (2016) Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. Oncotarget 7: 46158–46172. 10.18632/oncotarget.10064
    1. Heimesaat MM, Dunay IR, Fuchs D, Trautmann D, Fischer A, et al. (2011) The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. Eur J Microbiol Immunol (Bp) 1: 302–310.
    1. Wang W, Uzzau S, Goldblum SE, Fasano A (2000) Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 113 Pt 24: 4435–4440.
    1. van Rheenen PF, Van de Vijver E, Fidler V (2010) Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 341: c3369 10.1136/bmj.c3369
    1. Striz I, Trebichavsky I (2004) Calprotectin—a pleiotropic molecule in acute and chronic inflammation. Physiol Res 53: 245–253.

Source: PubMed

3
購読する